Stockholm, Sweden Monday, June 30, 2025, 10:00 Hrs [IST] ...

FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, on Friday announced that the US Food and Drug Administration ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, on Friday announced that the U.S. Food and Drug ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), and polyarticular juvenile idiopathic arthritis (pJIA) are the main diseases treated. Last year, ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Cimzia (certolizumab pegol) is a prescription injection that treats Crohn’s disease, arthritis, and other conditions. Learn about side effects, dosage, and more.

When receiving a diagnosis of a rheumatic musculoskeletal disease (RMD), people need a lot of information. Some need it all ...

The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and ...

Juvenile idiopathic arthritis (JIA) is a group of disorders that cause arthritis (stiff, swollen, painful joints) in children. Some types are also called juvenile rheumatoid arthritis (JRA) .